newsfilter
← Latest News
GlobeNewswire·

Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

BTCY
  • Biotricity Inc. reported financial results for the third quarter of fiscal 2026 ended December 31, 2025, noting sustained revenue growth driven by remote cardiac monitoring adoption.
  • Revenue increased 10.2% to $4 million from $3.6 million in the prior year period.
  • Gross margin improved to 81.5% from 76.4% in the prior year quarter due to recurring technology fee expansion, AI automation efficiencies, \& improved cloud cost structures.
  • Net loss decreased 13% to $1.1 million ($0.042 per share) from $1.3 million ($0.054 per share) in the corresponding prior year quarter.
  • The company achieved three consecutive quarters of positive EBITDA \& net operating income.
  • Recurring Technology-as-a-Service (TaaS) fees rose 7.4% to $3.6 million, representing 91.2% of total revenue.
  • Customer retention remains above 90%, with the app base scaling from 4,500 to over 44,000 users in two years.
  • The provider network now includes over 2,500 providers supporting 4 million patients annually.
  • FDA clearance for an AI clinical model leveraging over two trillion anonymized heartbeats is expected in the coming months.
  • Strategic regulatory approvals were secured in Canada, Saudi Arabia, \& Argentina to support international distribution partnerships.
  • A conference call to discuss results is scheduled for February 11, 2026, at 4:30 p.m. ET.